End-stage Renal Disease Clinical Trial
Official title:
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
Verified date | August 2021 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients on hemodialysis treatment experience increased levels of cardiovascular disease. In this study, investigators will be detecting hemodialysis induced circulatory stress using the CVInsight Patient Monitoring & Informatics System - InteloMed. This system consists of the CVInsight non-contact device and the CVInsight contact device that measures a patient's response to dialysis by looking at many physiological parameters such as heart rate, heart rate variability, respiratory rate, and how much oxygen the blood is carrying. Investigators would like to validate the mobile CVInsight non-contact device to the currently used standard CVInsight contact device to provide healthcare providers with a better understanding of its role in early detection of cardiovascular stress induced by hemodialysis.
Status | Terminated |
Enrollment | 14 |
Est. completion date | October 8, 2020 |
Est. primary completion date | October 8, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients receiving conventional thrice weekly maintenance HD - Age =18 years - Able to provide informed consent Exclusion Criteria: • Not meeting inclusion criteria |
Country | Name | City | State |
---|---|---|---|
Canada | London Health Sciences Centre | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute | Intelomed, Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mobile CVInsight validation against the CVInsight contact device by recording pulse rate trends | Validation of the mobile CVInsight with pulse rate from the CVInsight contact device | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Primary | Mobile CVInsight validation against the CVInsight contact device by recording pulse strength | Validation of the mobile CVInsight with pulse strength (derived from a photoelectric plethysmograph waveform) from the CVInsight contact device | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Primary | Mobile CVInsight validation against the CVInsight contact device by recording pulse irregularity | Validation of the mobile CVInsight with pulse irregularity (derived from the pulse wave signal) from the CVInsight contact device | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Primary | Mobile CVInsight validation against the CVInsight contact device by recording oxygen saturation | Validation of the mobile CVInsight with the percentage of oxygen carried in blood from the CVInsight contact device | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Primary | Mobile CVInsight validation against the CVInsight contact device by recording oxygen saturation variability | Validation of the mobile CVInsight with the oxygen saturation variability (derived from the oximeter signal) from the CVInsight contact device | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Secondary | Early detection of hemodialysis-induced circulatory stress using the CVInsight System | The secondary outcome will be assessment of the contact and non-contact CVInsight devices on hemodialysis induced circulatory stress | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Secondary | Early detection of hemodialysis-induced circulatory stress using the finometer | The secondary outcome will be assessment of the finometer on hemodialysis induced circulatory stress | Through dialysis session, an average of 4 hours for two separate visits within the same week. | |
Secondary | Early detection of hemodialysis-induced circulatory stress using echocardiography | The secondary outcome will be assessment of echocardiography on hemodialysis induced circulatory stress | Before the dialysis session and 15 minutes prior to the end of the dialysis session for two separate visits within the same week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087213 -
Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A | |
Not yet recruiting |
NCT02238093 -
Cardiorenal Syndrome in End-Stage Kidney Disease
|
N/A |